Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific...

Area of Science:

• Oncology
• Radiochemistry
• Molecular Imaging

Background:

• Small-molecule ligands targeting tumor-specific receptors are vital for cancer diagnosis and therapy.
• High-affinity binding is essential for improving detection and therapeutic effectiveness.
• The precise affinity needed for maximal target binding and retention in vivo remains undefined.

Purpose of the Study:

• To systematically investigate the impact of small-molecule affinity on tumor uptake in vivo.
• To establish design criteria for developing effective small-molecule agents for targeted cancer therapeutics.

Main Methods:

• Utilized a pretargeted bispecific antibody system as a receptor proxy.
• Tested small molecules with DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)-based chelators and varying binding affinities.
• Focused on a system targeting carcinoembryonic antigen (CEA) to evaluate tumor uptake at 24 hours postinjection.

Main Results:

• A small-molecule binding affinity of 400 pmol/L was sufficient to achieve maximal tumor targeting in the CEA-targeted system.
• Further increasing affinity to 10 pmol/L did not yield significant improvements in tumor uptake at 24 hours.
• A mathematical model correlating with experimental observations was developed to predict tumor targeting.

Conclusions:

• Optimal small-molecule affinity for maximal tumor targeting is achievable with specific binding affinities, not necessarily the highest possible.
• The developed mathematical model and derived design criteria can guide future development of targeted cancer therapeutics.
• Understanding affinity thresholds can optimize the design of small-molecule agents for improved cancer diagnosis and therapy.